HealthMedical News

Hearing Aids and Dementia Risk: What ACHIEVE and Newer Trials Actually Show

Key takeaways

  • Observational hearing-loss associations and randomized hearing-intervention results are different evidence.
  • ACHIEVE’s overall result and higher-risk subgroup result must be reported together.
  • CHOICE studied people with mild cognitive impairment and a different primary endpoint.
  • Better communication is valuable even when long-term dementia prevention remains uncertain.

If you have difficulty following conversation, a headline about hearing aids preventing dementia can sound like a compelling reason to act. It can also create unnecessary pressure to buy the most expensive device or assume that delaying a purchase has caused irreversible harm.

The hearing aids and dementia risk evidence deserves a more precise reading. Researchers have tested specific interventions in defined groups, using outcomes that range from cognitive scores to dementia-level impairment. The results do not fit one blanket promise.

Hearing care can be worthwhile for reasons that are meaningful now. Understanding those reasons alongside the trials helps you make a decision about communication, support and cost without treating a device as an insurance policy against dementia.

Why researchers study hearing and cognition together

Hearing loss is associated with cognitive decline in observational research, which motivated intervention trials such as ACHIEVE. An association alone cannot show that restoring access to sound will change the course of a neurodegenerative disease.

Different explanations can coexist. Hearing difficulty may affect participation or the effort required to follow speech, while other health factors may influence both hearing and cognition. A plausible explanation helps frame a trial; it cannot replace one.

Our cognitive reserve and aging guide discusses daily function and brain-health claims more broadly. Here, the narrower question is what happens when a defined hearing intervention is compared with a control.

What ACHIEVE tested

The 2023 ACHIEVE randomized trial enrolled 977 adults aged 70–84 with untreated hearing loss and without substantial cognitive impairment. Participants received either audiological counseling with hearing aids or a health-education intervention. The primary outcome was change in a global cognitive score over three years.

In the combined population, cognitive change did not differ significantly between groups. The study also included two recruitment populations: participants from the long-running ARIC cardiovascular cohort and healthier community volunteers recruited for the trial.

In a prespecified analysis, the ARIC group, which had more cognitive-risk factors, showed approximately 48% less cognitive decline with the hearing intervention. That percentage describes change in the study’s cognitive measure in that subgroup. It is not a 48% reduction in dementia incidence for everyone buying hearing aids.

How to read the subgroup finding

Both parts of ACHIEVE belong in the same explanation: the overall primary result was null, and the prespecified higher-risk subgroup showed a benefit. Reporting only one would give an incomplete picture.

A prespecified subgroup is more informative than searching many categories after seeing the data. Even so, its participants and outcome define its scope. You cannot determine that you match the subgroup simply because you feel worried about memory or have a family history.

The practical question for a clinician is how this evidence fits your actual hearing and health needs. The trial does not establish a consumer calculator that converts a hearing test into a guaranteed amount of dementia prevention.

A newer trial asked a different question

The 2026 CHOICE trial randomized 703 older adults in Shanghai who had both mild cognitive impairment and moderate-to-severe hearing loss. It compared a hearing-aid intervention with hearing-care education over 24 months.

Its primary outcome was progression to dementia-level impairment, defined using the Clinical Dementia Rating. The intervention did not significantly reduce that outcome. A prespecified secondary analysis found a higher rate of cognitive improvement in the intervention group.

This is not a contradiction to be solved by choosing the most attractive result. The primary and secondary outcomes have different roles. CHOICE also studied a population and endpoint different from ACHIEVE, so their percentages should not be treated as directly competing estimates of one universal effect.

What the trials do not establish

Neither trial justifies advertising every hearing aid as a device that preserves the brain. A clinical program includes more than hardware: the trial intervention, participant selection, support and follow-up all matter when interpreting its result.

The studies also do not establish that hearing care is pointless when the primary cognitive outcome is null. A person may value conversation, access to information and participation regardless of whether a trial demonstrates a long-term cognitive advantage.

Read negative and positive findings with the same discipline. A null result is not proof that no individual can benefit. A subgroup or secondary benefit is not proof that every intended purchaser will receive it.

Communication has its own evidence

A secondary ACHIEVE analysis published in 2024 examined self-reported communicative function. It reported improvement with the hearing intervention. This is a direct reason to discuss hearing care, while remaining a different outcome from dementia prevention.

The National Institute on Deafness and Other Communication Disorders explains that hearing aids can help people listen, communicate and participate in daily activities. It also describes limits: amplification does not restore normal hearing in every situation.

An achievable goal might therefore be following a particular conversation more easily, rather than expecting a device to reverse aging. Defining that goal makes it easier to judge fit and support. It also leaves room to discuss difficulties that persist after an initial fitting.

Match the claim to the outcome

StatementWhat evidence supports it?What should not be implied?
Hearing and cognition are linkedObservational researchHearing loss alone proves causation
A subgroup had less declinePrespecified ACHIEVE analysisEveryone has 48% less dementia risk
Dementia-level progression was not reduced significantlyCHOICE primary analysisHearing care has no practical value
Communication can improveHearing-care evidence and ACHIEVE secondary analysisNeurodegeneration has been reversed

Ask a seller which row its claim belongs to. If a product description quotes a cognitive trial, request the exact participant group and endpoint. A reference to a respected journal is not enough if the advertised outcome was not measured.

Make the purchase decision about your hearing needs

Start by describing the situations that are difficult: a conversation across a table, a meeting, television dialogue or speech in a noisy setting. Ask a hearing professional what the assessment suggests, what options fit the pattern and which limitations to expect.

Before paying, clarify fitting support, follow-up, returns, maintenance and the total cost. Ask what happens if the device is uncomfortable or does not help in the situation that matters most. A dementia-prevention slogan cannot replace those practical details.

Consider a hypothetical buyer whose main difficulty is following family conversation. A useful comparison would include comfort, speech access in that setting and the ability to obtain adjustments. Paying extra solely for an unsupported brain-preservation promise would not resolve those questions.

This is not a ranking of brands or a report of personal product testing. The trials reviewed here do not establish that one commercial model is the best dementia-prevention choice.

Over-the-counter access has a defined scope

The FDA’s OTC hearing-aid guidance describes this category for adults aged 18 or older with perceived mild-to-moderate hearing loss. It is not a route intended to replace evaluation for every kind or severity of hearing problem.

Sudden or rapidly worsening hearing loss and other concerning ear symptoms warrant medical attention rather than simply experimenting with a device. The NIDCD OTC guide explains when professional assessment is appropriate.

For ongoing memory concerns, ask about a separate clinical evaluation. Difficulty hearing instructions can complicate an assessment, but hearing loss should not automatically be used to explain every cognitive symptom. Tell the assessor about hearing difficulties and any devices you use.

Common questions about hearing aids and dementia risk

Can I say hearing aids cut dementia risk by 48%?

That wording misstates the cited ACHIEVE result. The percentage concerned relative reduction in cognitive decline over three years in a particular higher-risk subgroup. The overall primary result did not show a significant difference.

Does CHOICE mean hearing aids cannot help someone with mild cognitive impairment?

No. It did not significantly reduce its primary progression endpoint over 24 months, while a secondary outcome favored intervention. Communication needs and individual care decisions remain relevant.

What is the clearest reason to seek hearing care now?

Address a hearing difficulty that affects daily life and discuss appropriate options. Potential cognitive benefits can be part of an informed conversation, but should not become a guarantee, a source of blame or a reason to buy beyond your needs.

Sources and further reading

Continue reading

Share This Post:

Science Chronicle Editorial Team

Science Chronicle is published by eMarketLift LLC. Articles cite primary sources and separate research findings from practical suggestions. Read our editorial standards for how content is sourced, reviewed and corrected.

Avatar photo